MedPlus Health Services operates an omnichannel pharmacy retail network of 5,476 stores as of Q1 FY27, generating the vast majority of its revenue from pharmaceutical and non-pharmaceutical product sales. The company sits at the end of the healthcare value chain, utilizing a densification strategy in existing states to block competition and sweat its warehouse assets. Operating in a fragmented market with several national and regional players, the niche is a scale game where MedPlus competes on physical proximity and cost-plus private label pricing rather than switching costs. The economics currently reflect a retail operation transitioning to maturity, with a consolidated operating EBITDA margin of 3.5% in Q1 FY27 and a pharmacy operating EBITDA margin of 5.6% in Q4 FY26. However, mature stores older than 12 months demonstrate a store-level EBITDA margin of 10.4% to 13.1%, revealing that the blended margin is dragged down by new store ramp-up costs and indicating underlying operating leverage potential as the network ages.
The durability of this business stems from its asset replication strategy and localized distribution moat rather than specialized product economics. MedPlus has spent 18 months adding 10 new warehouses to support scalability, creating a physical infrastructure base that takes years and significant capital to replicate. The company maintains a NABL accredited lab to test every batch of its private label products, ensuring quality control across its 1,450-plus SKUs. Customer stickiness is evidenced by a 90% repeat business rate every 3 months for private label pharma and non-pharma products. The franchisee model further entrenches this physical network by allowing expansion without the operational drag of managing 25,000 additional employees, though it introduces partner onboarding constraints as franchisees must purchase inventory outright from MedPlus on day one.
The 18 to 24 month inflection hinges on scaling the franchisee network and shifting the product mix toward higher-margin private label offerings. By the end of FY27, management targets 800 net new store additions, heavily leveraging the franchisee model which yields a store-level EBITDA of 9.5% to 10% for MedPlus after supply chain costs. Over the next two years, the private label share is expected to grow by 20 to 30 basis points quarterly, expanding from 20% in Q1 FY27 toward a trajectory that approaches competitor non-pharma mixes of 30% to 50%. Every 50 basis points increase in private label sales is expected to lead to 10 to 20 basis points of gross margin accretion. By FY28, the concrete state of the business should feature a network exceeding 6,000 stores, consolidated operating EBITDA margins stabilizing between 5.7% and 6.7%, and mature store same-store sales growth of 9% to 10%, driven by a modernized footprint of 600-plus upgraded stores featuring smart rack systems.
Management's walk-talk reveals a mixed trajectory on volume targets but consistency on margin defense. In Nov 2025, management targeted 600 new stores for FY26 and 100 franchisee stores, later raising the FY27 target to 800 net new stores after adding 618 net stores in FY26 with 310 franchisee outlets. However, private label share guidance has been inconsistent, initially targeted at 1% quarterly growth but flattening at 22% for two straight quarters before management revised the target to 0.25% to 0.3% quarterly growth starting Q3 FY27. The company is zero-debt at the corporate level with INR4,956 million in operating cash flows in FY26, but capital allocation is constrained by high promoter leverage of approximately INR1,150 crores against pledged shares. Non-core capex, including a INR40 crore food park and wellness facility, has been officially put on hold to refocus on core pharmacy densification.
Earnings visibility depends on the franchisee model achieving scale without excessive closures and private label penetration recovering its growth trajectory. The quantified path targets a 6% pharmacy operating EBITDA margin over time, supported by a 10% overall same-store-sales-growth equivalent and a 1% reduction in customer discount structure effective July 2026. The single most important watchpoint is the wage inflation impact from significant increases effective June 1 in Karnataka (60%) and Telangana (25%+), which will pressure operating expenses in coming quarters. The tension between a 100 bps gross margin impact from lower private label mix and the expectation of EBITDA margin stabilization at 5.7% to 5.8% for FY27 must be resolved by the franchisee model offloading inventory and the subscription plan fee increase from INR99 to INR149 adding INR10 to INR11 crores annually. If franchisee closures, which stood at 27 outlets in Q1 FY27 with an average age of 0.7 years, accelerate beyond expectations, the capital-light growth thesis breaks.
companyname: MedPlus Health Services Limited ticker: MEDPLUS sector: Pharmacy Retail and Healthcare Services MedPlus Health Services Limited runs India's second-largest pharmacy retail chain. Founded in 2006 with 48 stores in Hyderabad, it ended FY26 with 5,330 stores across 13 states and one union territory, roughly 2.8 million square feet of retail space, and over 28,000 permanent employees. The company generates 98.1% of its revenue from retail pharmacy operations, with the balance from diag...
Read the full report →capex, margin expansion, geographic expansion
FY27 net new store additions guided at 800 stores (including franchisee outlets) driven by densification in existing states and expansion into new states
Guidance upgradedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for MedPlus Health Services Limited and 4,900+ companies.
5-day free pass. No card required.